Jonestrading Begins Coverage on Achieve Life Sciences (NASDAQ:ACHV)

Research analysts at Jonestrading initiated coverage on shares of Achieve Life Sciences (NASDAQ:ACHV) in a research note issued on Wednesday, Benzinga reports. The firm set a “buy” rating and a $20.00 price target on the biopharmaceutical company’s stock. Jonestrading’s price objective suggests a potential upside of 337.64% from the company’s current price.

Several other equities research analysts have also issued reports on the stock. Oppenheimer reissued an “outperform” rating and issued a $18.00 target price on shares of Achieve Life Sciences in a report on Monday, April 1st. Lake Street Capital cut their price objective on shares of Achieve Life Sciences from $19.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, March 5th.

Achieve Life Sciences Stock Performance

Achieve Life Sciences stock opened at $4.57 on Wednesday. The firm has a 50 day moving average of $4.42 and a 200 day moving average of $4.40. The firm has a market capitalization of $156.53 million, a price-to-earnings ratio of -2.99 and a beta of 1.32. Achieve Life Sciences has a 12-month low of $3.03 and a 12-month high of $10.30. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 4.02.

Institutional Investors Weigh In On Achieve Life Sciences

Institutional investors have recently added to or reduced their stakes in the stock. Manchester Financial Inc. grew its holdings in Achieve Life Sciences by 43.9% during the 3rd quarter. Manchester Financial Inc. now owns 18,600 shares of the biopharmaceutical company’s stock valued at $80,000 after buying an additional 5,675 shares in the last quarter. Raymond James & Associates grew its holdings in shares of Achieve Life Sciences by 6.3% in the third quarter. Raymond James & Associates now owns 146,100 shares of the biopharmaceutical company’s stock valued at $628,000 after purchasing an additional 8,615 shares in the last quarter. Morgan Stanley grew its holdings in shares of Achieve Life Sciences by 437.4% in the fourth quarter. Morgan Stanley now owns 13,547 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 11,026 shares in the last quarter. HRT Financial LP purchased a new position in shares of Achieve Life Sciences in the fourth quarter valued at $32,000. Finally, LPL Financial LLC grew its holdings in shares of Achieve Life Sciences by 48.4% in the fourth quarter. LPL Financial LLC now owns 148,300 shares of the biopharmaceutical company’s stock valued at $363,000 after purchasing an additional 48,400 shares in the last quarter. 33.52% of the stock is owned by hedge funds and other institutional investors.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.